Journal Article

Mibefradil — a drug which may enhance the propensity for the development of abnormal QT prolongation

T. Meinertz

in European Heart Journal Supplements

Published on behalf of European Society of Cardiology

Volume 3, issue suppl_K, pages K89-K92
Published in print September 2001 | ISSN: 1520-765X
Published online September 2001 | e-ISSN: 1554-2815 | DOI: http://dx.doi.org/10.1016/S1520-765X(01)90011-2
Mibefradil — a drug which may enhance the propensity for the development of abnormal QT prolongation

Show Summary Details

Preview

Mibefradil is a moral calcium antagonist that is selective for the T-type voltage-operated calcium channel. It has been shown to be effective in hypertension and in stable angina. Shortly following its introduction, mibefradil was withdrawn from the market because of potentially harmful interactions with other drugs. Of special interest is the possible interaction of mibefradil with drugs which prolong the QT interval (e.g. amiodarone, quinidine, sotalol, erythromycin, desimipramine and thioridazine).

This short review summarizes the effects of mibefradil on cardiac repolarization and possible implications for drug interactions with QT prolonging agents.

Keywords: Mibefradil; cardiac repolarization; drug interactions

Journal Article.  0 words. 

Subjects: Cardiovascular Medicine

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.